Risk of Fatigue in Adolescent and Young Adult Hodgkin Lymphoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01228461|
Recruitment Status : Completed
First Posted : October 26, 2010
Last Update Posted : April 4, 2017
Fatigue is one of the most prevalent symptoms endorsed by cancer survivors, particularly those treated for breast cancer or Hodgkin lymphoma. Despite the tremendous implications such work has for effective interventions, little is known about the underlying pathophysiology of fatigue, association with medical co-morbidities and factors that may help predict those to be at highest risk.
The proposed research will utilize Vanderbilt-Ingram Cancer Center REACH for Survivorship Program together with the investigators Hematologic Malignancies Program. In adolescent and young adults (AYA), ages 18 - 39 the investigators will address the following:
Primary Aims Aim 1: Assess the prevalence and severity of fatigue and its impact on functional outcomes Aim 2: Determine host, disease and treatment-related risk factors for fatigue
Secondary Aims Aim 1: Evaluate the association between levels of proinflammatory cytokine activity and fatigue Aim 2: Evaluate the association between fatigue and self reported fatigue in AYA Hodgkin lymphoma (HL) survivors.
- Fatigue is more prevalent and severe among AYA HL patients and survivors, compared to general population and will be associated with impaired functional outcome.
- Risk factors for fatigue include higher disease stage, B symptoms and elevated erythrocyte sedimentation rate at diagnosis, dose density of chemotherapy and higher doses and more expanded fields of radiotherapy.
- Risk of fatigue is associated with long-term cardiopulmonary and endocrine complications.
- Levels of specified proinflammatory cytokines are associated with increased fatigue.
|Condition or disease|
|Fatigue Hodgkin Lymphoma|
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
|AYA with Fatigue and Hodgkin Lymphoma|
- Prevalence and severity of fatigue and its impact on functional outcomes [ Time Frame: 1 year ]
- Evaluate the association between levels of proinflammatory cytokine activity and fatigue [ Time Frame: 1 year ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01228461
|United States, Tennessee|
|Vanderbilt University Medical Center|
|Nashville, Tennessee, United States, 37232|